Vetr upgraded shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a buy rating in a report published on Tuesday. The brokerage currently has $117.64 price target on the stock.

A number of other brokerages have also recently issued reports on JNJ. Zacks Investment Research cut shares of Johnson & Johnson from a buy rating to a hold rating in a research note on Thursday, August 4th. Jefferies Group lifted their price objective on shares of Johnson & Johnson from $113.00 to $119.00 and gave the company a hold rating in a research note on Thursday, August 4th. Deutsche Bank AG reissued a buy rating and issued a $142.00 price objective on shares of Johnson & Johnson in a research note on Friday, August 19th. BTIG Research reissued a neutral rating on shares of Johnson & Johnson in a research note on Wednesday, September 7th. Finally, Leerink Swann reissued a buy rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $121.03.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) opened at 112.48 on Tuesday. The stock has a 50 day moving average price of $115.85 and a 200-day moving average price of $118.43. The firm has a market cap of $306.01 billion, a P/E ratio of 19.74 and a beta of 0.75. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $0.02. The business had revenue of $17.80 billion for the quarter, compared to analysts’ expectations of $17.71 billion. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the firm posted $1.49 earnings per share. Equities research analysts forecast that Johnson & Johnson will post $6.72 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Upgraded by Vetr Inc. to Buy” was originally posted by Daily Political and is owned by of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this article can be viewed at http://www.dailypolitical.com/2016/11/30/johnson-johnson-jnj-upgraded-by-vetr-inc-to-buy.html.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be given a dividend of $0.80 per share. The ex-dividend date is Friday, November 18th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.29. This represents a $3.20 annualized dividend and a dividend yield of 2.84%. Johnson & Johnson’s payout ratio is presently 56.64%.

In other Johnson & Johnson news, Director Charles Prince bought 875 shares of the firm’s stock in a transaction dated Friday, October 21st. The stock was bought at an average cost of $114.11 per share, with a total value of $99,846.25. Following the completion of the transaction, the director now directly owns 26,520 shares in the company, valued at approximately $3,026,197.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.11% of the company’s stock.

Large investors have recently bought and sold shares of the company. Canandaigua National Bank & Trust Co. increased its stake in Johnson & Johnson by 0.3% in the first quarter. Canandaigua National Bank & Trust Co. now owns 97,516 shares of the company’s stock valued at $10,551,000 after buying an additional 291 shares during the last quarter. Royal Bank of Scotland Group PLC increased its stake in Johnson & Johnson by 1.7% in the first quarter. Royal Bank of Scotland Group PLC now owns 10,950 shares of the company’s stock valued at $1,184,000 after buying an additional 182 shares during the last quarter. USS Investment Management Ltd increased its stake in Johnson & Johnson by 38.9% in the first quarter. USS Investment Management Ltd now owns 211,814 shares of the company’s stock valued at $22,913,000 after buying an additional 59,314 shares during the last quarter. Shufro Rose & Co. LLC increased its stake in Johnson & Johnson by 22.8% in the first quarter. Shufro Rose & Co. LLC now owns 50,889 shares of the company’s stock valued at $5,506,000 after buying an additional 9,440 shares during the last quarter. Finally, Bessemer Group Inc. increased its stake in Johnson & Johnson by 77.1% in the first quarter. Bessemer Group Inc. now owns 748,552 shares of the company’s stock valued at $80,994,000 after buying an additional 325,913 shares during the last quarter. 64.13% of the stock is owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.